跳至主要内容
临床试验/NCT06968546
NCT06968546尚未招募2 期

Randomized Controlled Study Comparing Sufentanil and Ketamine Intranasally in the Management of Severe Acute Trauma-related Pain in Children.

Fondation Lenval1 个研究点 分布在 1 个国家目标入组 116 人开始时间: 2026年2月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
116
试验地点
1
主要终点
Change in pain intensity from baseline to 30 minutes after intranasal administration

研究概览

简要总结

Pain is one of the most common reasons for children to attend emergency departments, particularly following traumatic injuries such as fractures, sprains, or contusions. Despite advances in medical care, severe acute pain in children is still sometimes inadequately treated. One important reason is that intravenous pain medication can be technically difficult, stressful, or delayed in paediatric patients.

Intranasal drug administration, which involves spraying medication into the nose, offers a rapid and needle-free way to relieve pain and is increasingly used in paediatric emergency care. Two medications can be administered through this route: ketamine and sufentanil. Intranasal ketamine is already widely used in children for pain management. Sufentanil is a potent opioid analgesic commonly used in adults and in anaesthesia but has been much less studied in children when administered intranasally.

The aim of this study is to compare the effectiveness and safety of intranasal sufentanil and intranasal ketamine in children aged 6 to 17 years who present to the emergency department with severe traumatic limb pain. Both medications will be given in addition to standard care, including the routine use of an oxygen-nitrous oxide gas mixture (MEOPA), which is commonly used to reduce pain and anxiety in children.

Children who take part in the study will be randomly assigned to receive either intranasal sufentanil or intranasal ketamine. Pain levels will be assessed at regular time points after medication administration using age-appropriate pain scales. Sedation level and possible side effects will also be closely monitored for a short period following treatment.

The hypothesis of this study is that intranasal sufentanil will provide greater pain relief than intranasal ketamine 30 minutes after administration, without increasing the risk of adverse effects, when both are used alongside standard emergency care.

The results of this study are expected to improve knowledge about fast, effective, and non-invasive pain relief strategies for children in emergency settings and may help optimise future pain management protocols in paediatric emergency care.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Years 至 17 Years(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Children aged 6 to 17 years inclusive, under 18 years old, weighing more than 10kg, and requiring analgesia for the management of acute pain
  • •Presenting with pain assessed as severe using a validated pain scale (VAS > 6/10)
  • •Acute traumatic lime injury
  • •Pain caused by trauma, excluding thoracic trauma with dyspnea and abdominal pain
  • •Obtaining written and signe informed consent from one of the two parents or legal guardians
  • •Affiliation with a social security system
  • •Hemodynamically stable
  • •For post-menarche girls: negative urine pregnancy test and effective contraception, in accordance with national regulations

排除标准

  • •Patient in a state of immediate life-threatening distress
  • •Parents who don't understand and/or don't speak French
  • •Known hypersensitivity to opiods
  • •Allergy to one of the study treatments
  • •History of epilepsy or known psychiatric illness
  • •History of respiratory, cardiac or renal insufficiency
  • •Use of serotonergic antidepressants
  • •Any child with an ongoing respiratory condition (asthma, laryngitis)
  • •Thoracic trauma
  • •Use of opioids within the 4 hours prior to arrival in the ermergency department
  • •Any child with an ongoing respiratory condition (asthma, laryngitis)
  • •Thoracic trauma
  • •Use of opioids within the 4 hours prior to arrival in the ermergency department
  • •History of head, abdominal, or spinal trauma
  • •Confirmed pregnancy
  • •History of toxic substance use
  • •Facial or nasal trauma
  • •Whithdrawal of informed consent from the parents or legal guardian

研究组 & 干预措施

intranasal Ketamine

Active Comparator

干预措施: Intranasal Ketamine (IN) (Drug)

intranasal Sufentanil

Experimental

干预措施: Intranasal Sufentanil (Drug)

结局指标

主要结局

Change in pain intensity from baseline to 30 minutes after intranasal administration

时间窗: 30 minutes after the administration of the treatment.

Pain intensity will be measured using a validated 100-mm Visual Analogue Scale (VAS) appropriate for children aged 6 years and older. The baseline pain score (T0) will be recorded immediately before intranasal administration of the study medication. .

次要结局

  • Time to effective analgesia(every 5 minutes for the first 30 minutes)
  • Excessive sedation(every 5 minutes for the first 30 minutes)
  • Child-reported satisfaction with pain management(at 60 minutes)

研究者

发起方
Fondation Lenval
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验